Market Cap : 2.88 B | Enterprise Value : 2.44 B | PE Ratio : 28.89 | PB Ratio : 5.94 |
---|
NAS:CORT has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NAS:CORT has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Corcept Therapeutics's Accounts Receivable for the three months ended in Dec. 2020 was $26.2 Mil. Corcept Therapeutics's Revenue for the three months ended in Dec. 2020 was $85.7 Mil. Hence, Corcept Therapeutics's days sales outstanding for the three months ended in Dec. 2020 was 27.88.
During the past 13 years, Corcept Therapeutics's highest Days Sales Outstanding was 61.48. The lowest was 23.73. And the median was 44.26.
Corcept Therapeutics's days sales outstanding increased from Dec. 2019 (20.69) to Dec. 2020 (27.88).
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
* The bar in red indicates where Corcept Therapeutics's Days Sales Outstanding falls into.
Days sales outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
Accounts Receivable can be measured by Days Sales Outstanding.
Corcept Therapeutics's Days Sales Outstanding for the fiscal year that ended in Dec. 2020 is calculated as
Days Sales Outstanding | = | Accounts Receivable | / | Revenue | * | Days in Period |
= | 26.198 | / | 353.874 | * | 365 | |
= | 27.02 |
Corcept Therapeutics's Days Sales Outstanding for the quarter that ended in Dec. 2020 is calculated as:
Days Sales Outstanding | = | Accounts Receivable | / | Revenue | * | Days in Period |
= | 26.198 | / | 85.735 | * | 365 / 4 | |
= | 27.88 |
* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
No Headline